Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales

View ORCID ProfileDavid Hodgson, View ORCID ProfileMihaly Koltai, View ORCID ProfileFabienne Krauer, View ORCID ProfileStefan Flasche, View ORCID ProfileMark Jit, Katherine E. Atkins
doi: https://doi.org/10.1101/2022.08.24.22279152
David Hodgson
1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Hodgson
  • For correspondence: david.hodgson@lshtm.ac.uk
Mihaly Koltai
1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mihaly Koltai
Fabienne Krauer
1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabienne Krauer
Stefan Flasche
1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefan Flasche
Mark Jit
1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Jit
Katherine E. Atkins
1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
2Centre for Global Health, Usher Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease. A new and potentially longer-lasting monoclonal antibody, Nirsevimab, showed promising results in phase IIb/III trials. We evaluate the cost-effectiveness of Nirsevimab intervention programmes in England and Wales

Methods We used a dynamic model for RSV transmission, calibrated to data from England and Wales. We considered a suite of potential Nirsevimab programmes, including administration to all neonates (year-round); only neonates born during the RSV season (seasonal); or neonates born during the RSV season plus infants less than six months old before the start of the RSV season (seasonal + catch-up).

Results If administered seasonally to all infants at birth, we found that Nirsevimab would have to be priced less than £63 per dose for at least 50% certainty that it could cost-effectively replace the current Palivizumab programme, using an ICER threshold of £20,000/QALY. An extended seasonal programme which includes a pre-season catch-up becomes the optimal strategy below a £34/dose purchasing price for at least 50% certainty. At a purchasing price per dose of £5-32, the annual implementation costs of a seasonal programme could be as high as £2 million before a switch to a year-round strategy would be optimal.

Discussion Nirsevimab has the potential to be cost-effective in England and Wales not only for use in high-risk infants.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced are available online at https://github.com/dchodge/nambcea

https://github.com/dchodge/nambcea

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted August 24, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales
David Hodgson, Mihaly Koltai, Fabienne Krauer, Stefan Flasche, Mark Jit, Katherine E. Atkins
medRxiv 2022.08.24.22279152; doi: https://doi.org/10.1101/2022.08.24.22279152
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales
David Hodgson, Mihaly Koltai, Fabienne Krauer, Stefan Flasche, Mark Jit, Katherine E. Atkins
medRxiv 2022.08.24.22279152; doi: https://doi.org/10.1101/2022.08.24.22279152

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (140)
  • Cardiovascular Medicine (1950)
  • Dentistry and Oral Medicine (253)
  • Dermatology (185)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (702)
  • Epidemiology (11115)
  • Forensic Medicine (8)
  • Gastroenterology (628)
  • Genetic and Genomic Medicine (3189)
  • Geriatric Medicine (309)
  • Health Economics (563)
  • Health Informatics (2046)
  • Health Policy (864)
  • Health Systems and Quality Improvement (783)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12733)
  • Intensive Care and Critical Care Medicine (708)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (336)
  • Neurology (2996)
  • Nursing (165)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1559)
  • Ophthalmology (478)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (382)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2793)
  • Public and Global Health (5605)
  • Radiology and Imaging (1096)
  • Rehabilitation Medicine and Physical Therapy (635)
  • Respiratory Medicine (763)
  • Rheumatology (340)
  • Sexual and Reproductive Health (312)
  • Sports Medicine (289)
  • Surgery (346)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)